Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B

Caris Life Sciences, Inc.

Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.
Clinical cases ~59,200 (+18% YoY); gross margin improved 500 bps to 68%.
Raised 2026 revenue guidance to $1.03-1.04B (27-28% growth); reaffirmed ~20% clinical therapy selection volume growth.
Launched Caris Detect multi-cancer early detection blood test and Caris ChromoSeq for myeloid malignancies.
Share repurchase program of up to $100M authorized; $82.1M remains available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.